C0691000

Ceftriaxone sodium

Name: Ceftriaxone sodium
Brand: SIAL
Price: 178 EUR

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Ceftriaxone disodium salt hemi(heptahydrate)

Slide 1 of 1

Se connecter pour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

100 MG

178,00 €

Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.

Demander une commande groupée

A propos de cet article

Formule empirique (notation de Hill) :

C₁₈H₁₆N₈Na₂O₇S₃ · 3.5H₂O

Numéro CAS:

104376-79-6

Poids moléculaire :

661.60

Numéro CE :

277-930-0

Numéro MDL:

MFCD01750405

Code UNSPSC :

41116107

ID de substance PubChem :

329774815

Nomenclature NACRES :

NA.24

Principaux documents

Voir toute la documentation

Passer à

Service technique

Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.

Laissez-nous vous aider

Qualité

pharmaceutical primary standard

Famille d'API

ceftriaxone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

Clé InChI

PMRZKYOXTPBIQF-MAODNAKNSA-J

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Documents de référence

Matériaux de référence analytiques pour le contrôle qualité des produits pharmaceutiques

Étalons des instituts de métrologie et des pharmacopées

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article	BP976	1098184	PHR1382
C0691000 Ceftriaxone sodium	BP976 Ceftriaxone sodium	USP 1098184 Ceftriaxone sodium	Supelco PHR1382 Ceftriaxone Sodium
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard
manufacturer/tradename EDQM	manufacturer/tradename BP	manufacturer/tradename USP	manufacturer/tradename -
format neat	format neat	format neat	format neat
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical pharmaceutical small molecule	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)
API family ceftriaxone	API family ceftriaxone	API family ceftriaxone	API family ceftriaxone

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ceftriaxone sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1098184

Ceftriaxone sodium, United States Pharmacopeia (USP) Reference Standard

C0692000

Ceftriaxone impurity A, European Pharmacopoeia (EP) Reference Standard

1098195

Ceftriaxone sodium E-isomer, United States Pharmacopeia (USP) Reference Standard

BP976

Ceftriaxone sodium, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

GHS08,GHS07

Mention d'avertissement

Danger

Mentions de danger

H315,H317,H319,H334,H335

Conseils de prudence

P261 - P280 - P305 + P351 + P338 - P342 + P311

Classification des risques

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Leptospirosis acquired by tourists in Venice, Italy.

Filippo Lagi et al.

Journal of travel medicine, 20(2), 128-130 (2013-03-08)

We present the case of two Australian tourists aged 25 and 26 years who, after immersion in a canal in Venice, developed severe leptospirosis. After a 1-week history of fever, headache, myalgia, and vomiting they developed jaundice and renal failure.

Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.

Catherine A Ison et al.

The Lancet. Infectious diseases, 13(9), 762-768 (2013-06-15)

Effective treatment of gonorrhoea is fundamental to public health control; however, the ability of Neisseria gonorrhoeae to successively develop resistance to different treatments has hampered control efforts. The extended-spectrum cephalosporins--cefixime and ceftriaxone--have been recommended in the UK for treatment of

Selectively enhanced antibacterial effects and ultraviolet activation of antibiotics with ZnO nanorods against Escherichia coli.

Zhihui Luo et al.

Journal of biomedical nanotechnology, 9(1), 69-76 (2013-05-01)

In this paper, the selectively enhanced antibacterial effects of ZnO nanorods with several kinds of conventional medical antibiotics are investigated. Compares to gentamicin, clarithromycin and ofloxacin, ZnO nanorods could obviously achieve synergistic antibacterial effects with ceftriaxone against Escherichia coli (E.

One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500mg ceftriaxone in Sydney, Australia.

Phillip J Read et al.

Sexual health, 10(5), 460-462 (2013-09-14)

Emerging antimicrobial resistance within Neisseria gonorrhoeae (NG) is a significant global public health threat. Detection and investigation of treatment failures is a crucial component of the World Health Organisation's response to this challenge. We report the cases of two homosexual

Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain.

N Goire et al.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 18(14), 20444-20444 (2013-04-19)

Emergence and spread of Neisseria gonorrhoeae resistant to extended spectrum cephalosporins is a major problem threatening treatment of gonorrhoea and is further highlighted by the recent report of a second ceftriaxone-resistant N. gonorrhoeae strain (F89) in Europe, initially observed in

Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique